Idorsia has become the first drugmaker in the EU to claim approval for a drug for chronic insomnia in the dual orexin receptor antagonist class, ahead of rival drugs from Merck & Co and Eisai.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback